Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Futibatinib

2b452a2d-0926-54d5-a8b6-38d4daa3c2ec · FDA Approved · targets FGFR2

Futibatinib

MeasuredReference

Futibatinib targets FGFR2, FGFR3, FGFR1. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

FGFR2FGFR3FGFR1FGFR4RET

Top hallmarks

  • tumor promoting inflammation2.2k
  • proliferation1.4k
  • immune evasion1.3k

Top pathways disrupted

No pathway data.

Resistance landscape — Futibatinib

MeasuredReference

10 known oncogenic variants exist on Futibatinib's top targets — see detail for inhibition impact.

Open in new tab